RESUMO
Background: Chemotherapy-induced diarrhea (CID) is a major challenge during chemotherapy, which not only affects the quality of life, but also reduces the effectiveness of chemotherapy. Aims: To evaluate the clinical efficacy of Bifid triple viable capsules in the treatment of CID in malignant tumors by using meta - analysis. Methods: Randomized controlled trials (RCTs) on Bifid triple viable capsules for the treatment of CID were retrieved from CNKI, Wanfang, VIP, China Biology Medicine disc, Chinese Clinical Trial Registry, PubMed, Embase, Cochrane Library, Web of Science and ClinicalTrails databases from the date of database establishment to December 2022. According to the inclusion and exclusion criteria, literatures were screened, extracted, and the quality of literature was evaluated. Meta - analysis was performed by using Stata/MP 14.0 software. Results: A total of 10 RCTs including 790 patients were enrolled. Meta - analysis results showed that efficacy of Bifid triple viable capsules in the treatment of CID was significantly increased than that of controls (OR=2.22, 95% CI: 1.69 - 2.92, P<0.000 1), and serum endotoxin, tumor necrosis factor - α, D - lactic acid, diamine oxidase were significantly decreased in Bifid triple viable capsules group than in controls (P<0.05). Conclusions: The addition of Bifid triple viable capsules adjuvant to the original symptomatic treatment of CID can optimize the treatment efficacy.
RESUMO
Objective:To analyze the clinical phenotype and genotype characteristics of infantile spasm (IS) associated with UBA5 gene mutation. Methods:Four cases of IS caused by UBA5 gene variation diagnosed at the Department of Pediatrics, Peking University First Hospital from March 2017 to June 2019 were retrospectively analyzed.The clinical manifestations, electroencephalogram (EEG), brain magnetic resonance imaging (MRI), treatment, and follow-up results were summarized. Results:In this study, 4 cases (3 males and 1 female) were clinically diagnosed with IS and carried complex heterozygous variation of UBA5 gene.Genetic analysis confirmed that a total of 6 different mutation sites were found, five of which were unreported.All the 4 cases presented with epileptic spasms at the age of 1 d to 8 months after birth, and 2 cases had focal seizures during the course of disease.The EEG of 4 cases showed hypsarrhythmia and cluster or isolated epileptic spasms were detected.Of the 3 patients who had brain MRI results, 2 cases showed nonspecific abnormalities and 1 case was normal.All the 4 patients had developmental delayed before seizure onset, and regressed to varying degrees and made slow progress after onset.One case had microcephaly, and 3 cases had hypertonia.At the last follow-up, the age of the 4 patients ranged from 7 months to 6 years and 4 months.All 4 patients were treated with multiple antiepileptic drugs, but none of them were under control. Conclusions:Children with IS associated with UBA5 gene variation have an early onset age, often accompanied by developmental delayed, microcephaly, dystonia, and refractory seizures.